This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Memantine in Adult Autism Spectrum Disorder

This study has been terminated.
(Sponsor withdrew funds)
Forest Laboratories
Information provided by (Responsible Party):
Johns Hopkins University Identifier:
First received: March 1, 2010
Last updated: June 27, 2017
Last verified: June 2017
The purpose of this study is to see if memantine is helpful in managing problematic symptoms in adults with autism, Asperger's disorder, or Pervasive Developmental Disorder not otherwise specified (NOS).

Condition Intervention
Autism Asperger's Disorder Pervasive Developmental Disorder NOS Drug: memantine Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Memantine in Adult Autism Spectrum Disorder

Resource links provided by NLM:

Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:
  • Clinical Global Impression-Scale(CGI-S) [ Time Frame: 12 weeks ]

Enrollment: 4
Actual Study Start Date: February 2010
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Treatment as usual plus placebo
Drug: Placebo
Look-alike placebo
Active Comparator: memantine
Treatment as usual plus memantine
Drug: memantine
memantine 5-20 mg daily


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  • Participant is currently in treatment in the Johns Hopkins Bayview Medical Center (JHBMC)
  • Participant has a diagnosis of:

    • Autistic Disorder
    • Asperger's Disorder
    • Pervasive Developmental Disorder (PDD) NOS
  • Participant meets one of the following criteria:

    • CGI-S >= 4 (CGI-S: ________)
    • Participant has the following problematic behaviors (at least one) that might be expected to benefit from memantine:

      1. _____________________________________________
      2. _____________________________________________
      3. _____________________________________________

Exclusion criteria

The patient meets none of the following criteria (mark if absent):

  • Active seizures (Patients with a history of seizures, who have been seizure-free on an antiepileptic regimen for six months or more would be eligible).
  • Rett's Syndrome or Childhood Disintegrative Disorder
  • Active treatment with an acetylcholinesterase inhibitor
  • Prior or current treatment with memantine
  • Current treatment with lamotrigine
  • Genetic, metabolic or degenerative disorder (excepting Fragile X).
  • Brain malformation or known severe brain trauma
  • Pregnancy or breastfeeding
  • Glomerular Filtration Rate (GFR) < 30 mL/min
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01078844

United States, Maryland
Johns Hopkins Bayview
Baltimore, Maryland, United States, 21287
Sponsors and Collaborators
Johns Hopkins University
Forest Laboratories
Principal Investigator: Eric Samstad, MD Johns Hopkins University
  More Information

Responsible Party: Johns Hopkins University Identifier: NCT01078844     History of Changes
Other Study ID Numbers: NA_00015760
Study First Received: March 1, 2010
Results First Received: May 17, 2017
Last Updated: June 27, 2017

Keywords provided by Johns Hopkins University:
Asperger's Disorder
Pervasive Developmental Disorder NOS

Additional relevant MeSH terms:
Asperger Syndrome
Autistic Disorder
Autism Spectrum Disorder
Developmental Disabilities
Child Development Disorders, Pervasive
Pathologic Processes
Neurodevelopmental Disorders
Mental Disorders
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents processed this record on September 21, 2017